What this comparison tells you
Growth hormone-releasing hormone analogue
Sermorelin
EmergingSome studies in people exist. Important questions remain about benefit, safety, who it helps, or how long the effects last. This is not an approval or recommendation.- Evidence type
- Body changes, not proven benefits
- Approval
- This review found no current FDA-approved sermorelin product in the United States. Former Geref products were FDA-approved and are no longer sold. FDA said safety or effectiveness was not the reason for their withdrawal.
- Approved products
- None identified in the United States.
- Sports status
- Prohibited
- Sources used
- 5 sources
- Last reviewed
- July 23, 2026
Studies in people show a growth-hormone response. They do not prove broad anti-aging or muscle-building benefits. Former Geref products are no longer sold.
Ghrelin-receptor agonist · GH secretagogue
Ipamorelin
EmergingSome studies in people exist. Important questions remain about benefit, safety, who it helps, or how long the effects last. This is not an approval or recommendation.- Evidence type
- Health results; use not approved
- Approval
- Still being studied; no FDA-approved product identified
- Approved products
- None identified in the United States.
- Sports status
- Prohibited
- Sources used
- 4 sources
- Last reviewed
- July 23, 2026
A short human study measured growth-hormone release, but it did not prove health benefits. A different phase 2 study did not show benefit on its main or other measured outcomes.
How the evidence compares
These are separate questions, not one score. A peptide can be well understood in one area and uncertain in another.
Both peptide columns stay aligned. Read across each row to compare the same question. On smaller screens, each question shows both records together.
Each question shows both records together.
| Question checked | SermorelinEmerging | IpamorelinEmerging |
|---|---|---|
| Health benefitsDid people's health improve? | SermorelinLimited Older studies in children exist. Research does not show that current products slow aging, reduce body fat, or build muscle. | IpamorelinLimited A phase 2 trial did not show significant benefit on its key efficacy endpoint. |
| Body changes in peopleWhat body changes did studies in people measure? | SermorelinModerate Studies in people show that sermorelin can trigger growth-hormone release. A body response alone does not prove a health benefit. | IpamorelinModerate Dose-escalation work characterizes short-lived GH release in healthy volunteers. |
| Known risksWhat do we know about risks in people? | SermorelinLimited Past records do not fully show whether modern compounded products are safe. They also do not show the safety of long-term use for wellness. | IpamorelinLimited Route-specific data are sparse and FDA identifies serious safety concerns. |
| Exact productDo we know what the product contains and how well it was made? | SermorelinLimited FDA records clearly describe the former Geref products. The identity and quality of each current compounded product must be checked separately. | IpamorelinUnclear No approved formulation anchors identity, purity, or equivalence in the consumer market. |
| Approval statusIs there a reviewed product for a specific use? | Sermorelin This review found no current FDA-approved sermorelin product in the United States. Former Geref products were FDA-approved and are no longer sold. FDA said safety or effectiveness was not the reason for their withdrawal. | Ipamorelin Still being studied; no FDA-approved product identified |
Questions to ask before you compare
Use these questions to see whether the records match.
- 01
Which body signal does each peptide act on?
- 02
Did a study in people test a health result, or only a hormone change?
- 03
Has either one ever had an FDA-approved product?
- 04
What safety and sports-rule limits apply?
What sources were used
The number of sources does not prove strength. Different sources answer different questions. A drug label, a trial, a cell study, and an agency review do not mean the same thing.
Sermorelin
5 sources used
- Regulatory2
- Anti-doping1
- FDA review1
- Science review1
Studies in people show that sermorelin can trigger growth-hormone release. Older studies in children found limited growth results. A hormone response is not the same as a health benefit. These studies do not prove benefits for current compounded products.
Reliable studies do not show that current compounded sermorelin products slow aging or build muscle. They also do not show less body fat, better sleep, or that people live longer.
Ipamorelin
4 sources used
- Anti-doping1
- Human pharmacology1
- Randomized trial1
- Regulatory1
The short hormone-response study was in healthy male volunteers. The phase 2 study was after bowel surgery. A dose-escalation study in healthy male volunteers characterized ipamorelin exposure and a short episode of GH release. In a multicenter, double-blind, placebo-controlled phase 2 trial after bowel surgery, the drug was described as well tolerated in that setting but did not significantly improve the key or secondary efficacy outcomes.
Those studies do not establish popular claims about muscle gain, fat loss, recovery, anti-aging, or sleep. They also do not establish the safety or quality of consumer products, compounded combinations, or different routes.
Fact checks for each peptide
Each result applies only to the statement shown. Open its record to see the version and sources.
Sermorelin
“Sermorelin was once FDA-approved.”
FDA records document the former Geref approvals. FDA later found that safety or effectiveness was not the reason for withdrawal.
- Evidence used
- Official record or product label
- What this result covers
- Historical Geref products, not current compounded sermorelin.
“Sermorelin raises growth hormone, so it is proven to slow aging.”
A hormone response cannot show that people live longer or age more slowly.
- Evidence used
- Studies of body changes in people
- What this result covers
- Hormone-response evidence cannot establish longer life or slower biological aging.
“Compounded sermorelin is an FDA-approved Geref generic.”
A former Geref approval does not make current compounded products FDA-approved. Current compounded products are not automatically the same as the former Geref products.
- Evidence used
- Official record or product label
- What this result covers
- Current products marketed after Geref withdrawal.
Ipamorelin
“Ipamorelin stimulates GH release in people.”
A human dose-escalation study measured an episode of GH release. That is a pharmacodynamic effect.
- Evidence used
- Studies of body changes in people
- What this result covers
- Short-term GH pharmacodynamics in the healthy volunteers and route studied.
“A GH response proves better recovery or body composition.”
A biomarker response is not a clinical outcome, and the identified studies did not establish those benefits.
- Evidence used
- No reliable studies showing this health result in people
- What this result covers
- Recovery and body-composition outcomes not established by GH pharmacology or the postoperative-ileus trial.
“Ipamorelin worked in its phase 2 surgical trial.”
The randomized trial reported no significant difference from placebo on its key and secondary efficacy analyses.
- Evidence used
- Health results from a study with randomly assigned groups
- What this result covers
- The postoperative-ileus population, intervention, and efficacy endpoints in the phase 2 trial.
Products with the same ingredient can differ
Evidence applies to the exact product used in a study. Check the peptide's amino-acid order, ingredients and form, how it enters the body, and where it came from. A shared ingredient name does not prove that another vial has the same benefits or risks.
Sermorelin
29 amino acids · GHRH fragment
A former Geref approval does not make a current product FDA-approved. Current compounded sermorelin products are not automatically the same as the former Geref products.
No FDA product label was found for this molecule in the sources reviewed.
- Historical diagnostic and pediatric growth-hormone-deficiency uses
Ipamorelin
Synthetic pentapeptide · investigational
Human studies used defined study material and routes. They do not establish the identity, safety, or equivalence of compounded mixtures or consumer-market products.
No FDA product label was found for this molecule in the sources reviewed.
- No FDA-approved indication
Sports rules and safety limits
These statuses do not give personal clearance to compete.
Sermorelin
The 2026 WADA list names sermorelin as a prohibited growth hormone-releasing hormone analogue.
Reviewed Read the governing record ↗Approval of a former product does not prove the quality of a current product. This guide gives no dose, injection, or compounding instructions.
Ipamorelin
Growth-hormone secretagogues and mimetics are prohibited under the current WADA framework.
Reviewed Read the governing record ↗FDA identifies immunogenicity, aggregation, impurity, and characterization concerns. The agency also cites serious adverse events, including death, in intravenous gastric-motility research and says it lacks sufficient information for other promoted injectable routes.
Two ways to trigger growth hormone
Sermorelin is a 29-amino-acid piece of growth hormone-releasing hormone (GHRH). GHRH is a body signal that tells the body to release growth hormone.
Ipamorelin is a lab-made peptide with five amino acids. It acts on the ghrelin receptor, which is a different signal pathway. This also leads to growth-hormone release.
Both are graded Emerging. Sermorelin's human evidence is mostly about hormone response. Ipamorelin has a hormone-response study and one clinical trial that tested a health outcome.
Approval history
Sermorelin was once FDA-approved as Geref. Those products were later discontinued. In 2013, FDA said safety or effectiveness was not the reason they were withdrawn. The July 23, 2026 review found no current FDA-approved sermorelin product.
No FDA-approved ipamorelin product was identified in its July 23, 2026 review. Its record lists no approved use.
A past approval does not make a product sold today approved. The claim that compounded sermorelin is an FDA-approved Geref generic is graded Misleading.
What studies in people found
Studies in people show that sermorelin can trigger growth-hormone release. Older studies in children with growth hormone deficiency found limited growth results.
A dose study in healthy male volunteers measured a short burst of growth-hormone release after ipamorelin. The claim that ipamorelin stimulates growth-hormone release in people is graded Supported with scope.
Ipamorelin was also tested in a phase 2 trial after bowel surgery. People were randomly assigned to ipamorelin or a placebo, and neither they nor the researchers knew who got which. The trial found no significant benefit on its main or other measured outcomes. The claim that ipamorelin worked in that trial is graded Misleading.
A hormone response is a body measurement. It does not prove a health benefit. The claim that a growth-hormone response proves better recovery or body composition is graded Not established for ipamorelin. The claim that sermorelin is proven to slow aging is graded Misleading.
Safety, product, and sports limits
FDA identifies several concerns with ipamorelin: possible immune reactions, peptide clumping (aggregation), impurities, and gaps in how the substance is characterized. FDA also cites serious adverse events, including death, in research that gave it into a vein for stomach movement problems.
FDA says it lacks enough information about other injection routes that sellers promote for ipamorelin. Sermorelin's past records do not show whether modern compounded products are safe.
No approved product anchors the identity or quality of ipamorelin sold today. Each compounded sermorelin product must be checked on its own.
Sermorelin is banned for athletes covered by the World Anti-Doping Code. The 2026 WADA list names it. Ipamorelin falls under the growth-hormone secretagogues that the current WADA framework prohibits. No dose, injection, or compounding instructions are given here.
What these records cannot answer
- The reviewed records contain no study that compares sermorelin with ipamorelin directly, so no result comparison is made.
- Neither record includes adverse-event rates that can be compared between the two.
- The records give no dosing, injection, cycling, or stacking guidance, and none is given here. No study of the two used together is recorded.
- The reviewed records contain no cost, insurance, or availability data, so none is reported.
This page does not provide dosing, sourcing, or treatment advice.
Read the sources behind the comparison
Sermorelin
Ipamorelin